New drug safety watch for kids with rare blood disorder

NCT ID NCT06287268

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is monitoring the safety and effectiveness of the drug eltrombopag in children with aplastic anemia who are starting a specific treatment for the first time. It will follow about 10 children, aged 6 to 18, for one year to track any side effects and see how well their blood counts improve. The goal is to gather real-world information on how this drug works in young patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site
RECRUITING

Toyoake, Aichi-ken, 4701192, Japan
Novartis Investigative Site
RECRUITING

Chiba, Chiba, 260 8677, Japan
Novartis Investigative Site
RECRUITING

Amagasaki, Hyōgo, 660 8550, Japan
Novartis Investigative Site
RECRUITING

Kobe, Hyōgo, 6500047, Japan
Novartis Investigative Site
RECRUITING

Matsumoto, Nagano, 3908621, Japan
Novartis Investigative Site
RECRUITING

Shimajiri-Gun, Okinawa, 901-1303, Japan
Novartis Investigative Site
RECRUITING

Izumi, Osaka, 5941101, Japan
Novartis Investigative Site
RECRUITING

Osaka, Osaka, 5340021, Japan
Novartis Investigative Site
RECRUITING

Sakai, Osaka, 590-0197, Japan
Novartis Investigative Site
RECRUITING

Saitama, Saitama, 3308777, Japan
Novartis Investigative Site
RECRUITING

Ohtsu, Shiga, 5202192, Japan
Novartis Investigative Site
RECRUITING

Chuo Ku, Tokyo, 1048560, Japan
Novartis Investigative Site
RECRUITING

Ōta-ku, Tokyo, 143 8541, Japan
Novartis Investigative Site
RECRUITING

Setagaya-ku, Tokyo, 1578535, Japan
Novartis Investigative Site
RECRUITING

Wakayama, Wakayama, 641-8510, Japan

Conditions

Explore the condition pages connected to this study.

APLASTIC ANEMIA